Gov. Evers Highlights Risks of Federal Hemp Regulations in Wisconsin
Federal hemp regulations allowing delta-9 THC products to remain largely unregulated create patient safety concerns in Wisconsin. Clinicians face challenges due to unknown potency and contaminants in hemp products. Understanding federal hemp regulations…
Study Reveals Risks of Infrequent Cannabis Use in Adolescents
Infrequent adolescent cannabis use risks include measurable declines in academic performance and mental health outcomes. This study challenges assumptions about safe cannabis use thresholds in youth. Clinicians should counsel families that even…
Epic Handshake
Further Reading Cannabis NewsRecreational drugs triple the risk of stroke in young people, study finds | The IndependentEvidence WatchDaily Digest 2026-03-08CED Clinic BlogCannabis-Infused Beverages as Alcohol Alternatives: New York at Five Years …
Is This a Pigeon
# “Is This a Pigeon” Me, squinting at lab results: “Is this a clinically significant cannabinoid ratio, or just my patient’s interpretation of the budtender’s recommendation?” Further Reading Cannabis NewsRecreational…
Buff Doge vs Cheems
**Buff Doge:** “Peer-reviewed endocannabinoid research” vs. **Cheems:** “My cousin said it cured his thing” The evidence base has entered the chat, and it’s aggressively ripped. Further Reading Cannabis NewsRecreational…
Why Cannabis Rescheduling Alone Won’t Stabilize the Industry
The cannabis rescheduling impact could remove federal barriers to clinical research, enabling better prescribing decisions. However, without regulatory clarity, product consistency remains a challenge. Cannabis rescheduling impact alone won't stabilize…
Avecho Biotechnology Hits Milestone in Phase 3 Insomnia Trial
Avecho Biotechnology has reached a crucial milestone in its phase 3 insomnia trial cannabidiol study. This large-scale trial aims to provide robust efficacy and safety data for CBD as a treatment option. Clinicians should monitor this trial as it may…
In the Mix: 7 More Articles — March 03, 2026
This article reviews cannabis regulatory enforcement challenges impacting clinical relevance in 2026. It highlights illicit market enforcement and compliance issues. Understanding these challenges is key for clinicians advising patients on cannabis use.
Daily Digest: Last 15 Hours: Pharmaceutical Standards, Cognitive Safety, and Policy Gaps — March 03, 2026
This digest highlights pharmaceutical standardization cannabinoid therapeutics as a key theme in recent cannabis research. It discusses clinical-grade cannabis and the gap between medicine and policy. The focus is on improving patient access through…
Linnea Achieves CEP Certification for Cannabidiol Isolate – Morningstar
CEP certification cannabidiol isolate establishes pharmaceutical-grade quality standards for CBD, ensuring consistent drug formulation and regulatory compliance. This certification addresses historical variability in cannabis-derived therapeutics,…